Gene Polymorphism of IL17 and IL 23 (COVID 19IL17)

October 24, 2022 updated by: Noha Saber Shafik, Sohag University

Association Between Gene Polymorphism of IL17 and IL 23 in Patients With COVID 19

rates are in such considerable amount among large population base. The pathogenesis of COVID-19 implicates a potent inflammatory response, involving a complex group of mediators including interleukins. These pleiotropic cytokines are secreted at the region of inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells during sepsis and acute organ injuries. There has recently found a number of studies reporting that the cytokine storms take part in the course of COVID-19

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Aim Of The Study

  1. To evaluate if there is an association between the IL-17, IL-23 gene polymorphism in Patients With COVID 19 by real-time PCR
  2. To measure the serum level of IL17 by ELISA in COVID 19 patients by ELISA.
  3. To detect if there is an association between gene polymorphism of IL17 and IL23 and severity of a condition in patients with COVID 19 Study design: a cross-sectional study.

The blood samples will be collected from patient records in COVID19 isolation hospitals in sohag governorate and isolation department in sohag university hospitals.

Study Type

Observational

Enrollment (Actual)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt, 82733
        • Sohag University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

group 1 patients with covid 19 with severe infections admitted at ICU group 2 patients with covid 19 with nonsevere infections admitted at internal wards

Description

Inclusion Criteria:

  • Patients with Covid19 positive PCR

Exclusion Criteria:

  • Patients with Covid19 clinical criteria not confirmed by PCR

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
group 1 patients with severe covid 19 respiratory infections
Patients with severe covid 19 admitted to ICU, blood samples will be collected for testing different genotypes and serum level of IL 17
Diagnostic test: laboratory test
genotyping of IL 17 and IL23
Diagnostic test: laboratory test
estimation of serum level of IL 17
group 2 patients with non severe covid 19 respiratory infections
Patients with nonsevere covid 19 admitted to the internal ward, blood samples will be collected for testing different genotypes and serum level of IL 17
Diagnostic test: laboratory test
genotyping of IL 17 and IL23
Diagnostic test: laboratory test
estimation of serum level of IL 17

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
genotyping of IL 17
Time Frame: 3-6-2021 to 30-8-2021
real time pcr detection of different genotypes
3-6-2021 to 30-8-2021
genotyping of IL 23
Time Frame: 3-6-2021 to 30-8-2021
real time pcr detection of different genotypes
3-6-2021 to 30-8-2021
estimation of serum level of IL 17
Time Frame: 3-6-2021 to 30-8-2021
measuring serum level of IL 17 by ELISA
3-6-2021 to 30-8-2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

  • Principal Investigator: N S shafik, lecturer, Sohag university Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 3, 2021

Primary Completion (Actual)

November 30, 2021

Study Completion (Actual)

December 3, 2021

Study Registration Dates

First Submitted

June 24, 2021

First Submitted That Met QC Criteria

June 24, 2021

First Posted (Actual)

July 2, 2021

Study Record Updates

Last Update Posted (Actual)

October 25, 2022

Last Update Submitted That Met QC Criteria

October 24, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-21-04-35

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

to protect the privacy of the patient

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19 Respiratory Infection

Clinical Trials on laboratory test

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe